Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2022 - 10 - 27 save search
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2022-10-27 (Crawled : 23:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: -0.94%
H: 1.9%
C: -0.95%
rubraca trial cancer prostate cancer
Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.
Published: 2022-10-27 (Crawled : 17:00) - biospace.com/
TSOI | $0.0007 0.0% 23M
|
Manufacturing
|
| O: 5.5%
H: 0.0%
C: -10.43%
solutions immunotherapy cancer international
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
Published: 2022-10-27 (Crawled : 12:00) - biospace.com/
CSTL | $19.86 -1.0% -0.85% 110K
|
Health Technology
|
| O: 0.27%
H: 0.43%
C: -1.35%
collaboration program results cancer
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
Published: 2022-10-27 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 1.56%
H: 0.96%
C: -2.11%
biotech cancer
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
Published: 2022-10-27 (Crawled : 12:00) - biospace.com/
NVTA | News | $0.019 0.0% 22M
|
Health Services
|
| O: 0.6%
H: 1.8%
C: -8.62%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: -0.12%
partnership rare research cancer
MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Published: 2022-10-27 (Crawled : 11:00) - prnewswire.com
VRAY | $0.025 -39.9% -61.87% 110M
|
Health Technology
|
| O: 2.34%
H: 0.23%
C: -4.79%
mridian trial cancer prostate cancer
Breast Cancer Therapeutics Market Size to Grow by USD 13.85 Bn, Targeted Therapy to be Largest Revenue-generating Product Segment - Technavio
Published: 2022-10-27 (Crawled : 07:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 1.47%
H: 0.21%
C: -0.7%
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
|
| O: 0.1%
H: 0.85%
C: -1.1%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.06%
H: 0.44%
C: -0.15%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.12%
H: 0.47%
C: 0.21%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.82%
H: 0.15%
C: -0.17%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
PBYI | $4.83 -5.85% -5.99% 370K
|
Health Technology
|
| O: 1.32%
H: 0.43%
C: -3.46%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: -0.12%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.5%
H: 0.49%
C: -0.29%
breast therapeutics therapy cancer market
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.